Is age-related macular degeneration a manifestation of systemic disease? New prospects for early intervention and treatment

Journal of Internal Medicine

Volumn 276, Issue 2, 2014, Pages 140-153

  Cheung, C M G ^a,b,c   Wong, T Y ^a,b,c,d  

^a SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^b SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Age related macular degeneration; Pathogenesis; Risk factors; Treatment

Indexed keywords

CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DYSLIPIDEMIA; EARLY INTERVENTION; GENERAL PRACTITIONER; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK FACTOR; SYSTEMIC DISEASE;

AGE-RELATED MACULAR DEGENERATION; PATHOGENESIS; RISK FACTORS; TREATMENT;

AGED; AGING; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; INCIDENCE; INFLAMMATION; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; META-ANALYSIS AS TOPIC; NEURODEGENERATIVE DISEASES; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SMOKING; TREATMENT OUTCOME; WORLD HEALTH;

EID: 84904293663     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12227     Document Type: Review

References (160)

1. Bourne RRA, Stevens GA, White RA et al. Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet Global Health 2013; 1: e339-49.
2. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet 2012; 379: 1728-38.
3. Wong TY, Chakravarthy U, Klein R et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008; 115: 116-26.
4. Velez-Montoya R, Oliver SC, Olson JL, Fine SL, Quiroz-Mercado H, Mandava N. Current knowledge and trends in age-related macular degeneration: genetics, epidemiology, and prevention. Retina 2013; 33: 1487-502.
5. Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-44.
6. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31.
7. Heier JS, Brown DM, Chong V et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119: 2537-48.
8. Group CR, Martin DF, Maguire MG et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-908.
9. Chakravarthy U, Harding SP, Rogers CA et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013; 382: 1258-67.
10. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 2012; 153: 209-13.
11. Belkin M, Kalter-Leibovici O, Chetrit A, Skaat A. Time trends in the incidence and causes of blindness in Israel. Am J Ophthalmol 2013; 155: 404.
12. Wong TY. Age-related macular degeneration: why should stroke physicians care? Stroke 2010; 41: 575-6.
13. Baird PN, Chakrabarti S. How genetic studies have advanced our understanding of age-related macular degeneration and their impact on patient care: a review. Clin Experiment Ophthalmol 2014; 42: 53-64.
14. Wong TY, Hyman L. Population-based studies in ophthalmology. Am J Ophthalmol 2008; 146: 656-63.
15. Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 2007; 114: 253-62.
16. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004; 137: 486-95.
17. Wang JJ, Rochtchina E, Lee AJ et al. Ten-year incidence and progression of age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology 2007; 114: 92-8.
18. Klein R, Klein BE, Franke T. The relationship of cardiovascular disease and its risk factors to age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1993; 100: 406-14.
19. Klein R, Klein BE, Tomany SC, Meuer SM, Huang GH. Ten-year incidence and progression of age-related maculopathy: the Beaver Dam eye study. Ophthalmology 2002; 109: 1767-79.
20. Klein R, Rowland ML, Harris MI. Racial/ethnic differences in age-related maculopathy. Third National Health and Nutrition Examination Survey. Ophthalmology 1995; 102: 371-81.
21. Chen SJ, Cheng CY, Peng KL et al. Prevalence and associated risk factors of age-related macular degeneration in an elderly Chinese population in Taiwan: the Shihpai Eye Study. Invest Ophthalmol Vis Sci 2008; 49: 3126-33.
22. You QS, Xu L, Yang H et al. Five-year incidence of age-related macular degeneration: the Beijing Eye Study. Ophthalmology 2012; 119: 2519-25.
23. Kawasaki R, Wang JJ, Ji GJ et al. Prevalence and risk factors for age-related macular degeneration in an adult Japanese population: the Funagata study. Ophthalmology 2008; 115: 1376-81.
24. Yasuda M, Kiyohara Y, Hata Y et al. Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the Hisayama study. Ophthalmology 2009; 116: 2135-40.
25. Christen WG, Glynn RJ, Chew EY, Buring JE. Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women. Ophthalmology 2009; 116: 2386-92.
26. Cho BJ, Heo JW, Kim TW, Ahn J, Chung H. Prevalence and risk factors of age-related macular degeneration in Korea: the Korean national health and nutrition examination survey. Invest Ophthalmol Vis Sci. 2014; 55: 1101-8.
27. Kawasaki R, Yasuda M, Song SJ et al. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 2010; 117: 921-7.
28. Rudnicka AR, Jarrar Z, Wormald R, Cook DG, Fletcher A, Owen CG. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology 2012; 119: 571-80.
29. Erke MG, Bertelsen G, Peto T, Sjolie AK, Lindekleiv H, Njolstad I. Prevalence of age-related macular degeneration in elderly Caucasians: the Tromso Eye Study. Ophthalmology 2012; 119: 1737-43.
30. Geirsdottir A, Stefansson E, Jonasson F, Helgadottir G, Sigurdsson H. Age-related macular degeneration in very old individuals with family history. Am J Ophthalmol 2007; 143: 889-90.
31. Buch H, Nielsen NV, Vinding T, Jensen GB, Prause JU, la Cour M. 14-year incidence, progression, and visual morbidity of age-related maculopathy: the Copenhagen City Eye Study. Ophthalmology 2005; 112: 787-98.
32. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119: 1417-36.
33. van Lookeren Campagne M, Lecouter J, Yaspan BL, Ye W. Mechanisms of age-related macular degeneration and therapeutic opportunities. J Pathol 2014;232: 151-64.
34. Chakravarthy U, Wong TY, Fletcher A et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol 2010; 10: 31.
35. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003; 48: 257-93.
36. Tomany SC, Wang JJ, Van Leeuwen R et al. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology 2004; 111: 1280-7.
37. Klein R, Cruickshanks KJ, Myers CE et al. The relationship of atherosclerosis to the 10-year cumulative incidence of age-related macular degeneration: the Beaver Dam studies. Ophthalmology 2013; 120: 1012-9.
38. Gorin MB. Genetic insights into age-related macular degeneration: controversies addressing risk, causality, and therapeutics. Mol Aspects Med 2012; 33: 467-86.
39. Gemmy Cheung CM, Li X, Cheng CY et al. Prevalence and risk factors for age-related macular degeneration in Indians: a comparative study in Singapore and India. Am J Ophthalmol 2013;155: 764-73.
40. Pan CW, Ikram MK, Cheung CY et al. Refractive errors and age-related macular degeneration: a systematic review and meta-analysis. Ophthalmology 2013; 120: 2058-65.
41. Hyman L, Schachat AP, He Q, Leske MC. Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. Arch Ophthalmol 2000; 118: 351-8.
42. Wong T, Mitchell P. The eye in hypertension. Lancet 2007; 369: 425-35.
43. Klein R, Deng Y, Klein BE et al. Cardiovascular disease, its risk factors and treatment, and age-related macular degeneration: Women's Health Initiative Sight Exam ancillary study. Am J Ophthalmol 2007; 143: 473-83.
44. Age-Related Eye Disease Study Research G. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology 2000; 107: 2224-32.
45. Klein R, Klein BE, Marino EK et al. Early age-related maculopathy in the cardiovascular health study. Ophthalmology 2003; 110: 25-33.
46. Cougnard-Gregoire A, Delyfer MN, Korobelnik JF et al. Long-term blood pressure and age-related macular degeneration: the ALIENOR study. Invest Ophthalmol Vis Sci 2013; 54: 1905-12.
47. van Leeuwen R, Ikram MK, Vingerling JR, Witteman JC, Hofman A, de Jong PT. Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam study. Invest Ophthalmol Vis Sci 2003; 44: 3771-7.
48. Choudhury F, Varma R, McKean-Cowdin R, Klein R, Azen SP, Los Angeles Latino Eye Study Group. Risk factors for four-year incidence and progression of age-related macular degeneration: the Los Angeles Latino Eye study. Am J Ophthalmol 2011; 152: 385-95.
49. Tan JS, Mitchell P, Smith W, Wang JJ. Cardiovascular risk factors and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye study. Ophthalmology 2007; 114: 1143-50.
50. van Leeuwen R, Tomany SC, Wang JJ et al. Is medication use associated with the incidence of early age-related maculopathy? Pooled findings from 3 continents. Ophthalmology 2004; 111: 1169-75.
51. Wong TY, Tikellis G, Sun C, Klein R, Couper DJ, Sharrett AR. Age-related macular degeneration and risk of coronary heart disease: the Atherosclerosis Risk in Communities study. Ophthalmology 2007; 114: 86-91.
52. Hogg RE, Woodside JV, Gilchrist SE et al. Cardiovascular disease and hypertension are strong risk factors for choroidal neovascularization. Ophthalmology 2008; 115: 1046-52.
53. Klein R, Klein BEK, Tomany SC, Cruickshanks KJ. The association of cardiovascular disease with the long-term incidence of age-related maculopathy. Ophthalmology 2003; 110: 636-43.
54. Grosso A, Mosley TH, Klein R et al. Is early age-related macular degeneration associated with cerebral MRI changes? The Atherosclerosis Risk in Communities study. Am J Ophthalmol 2007; 143: 157-9.
55. Sivak JM. The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease. Invest Ophthalmol Vis Sci 2013; 54: 871-80.
56. Ohno-Matsui K. Parallel findings in age-related macular degeneration and Alzheimer's disease. Prog Retin Eye Res 2011; 30: 217-38.
57. Woo SJ, Park KH, Ahn J et al. Cognitive impairment in age-related macular degeneration and geographic atrophy. Ophthalmology 2012; 119: 2094-101.
58. Wong TY, Klein R, Sharrett AR et al. Retinal microvascular abnormalities and cognitive impairment in middle-aged persons: the Atherosclerosis Risk in Communities study. Stroke 2002; 33: 1487-92.
59. Keenan TD, Goldacre R, Goldacre MJ. Associations between age-related macular degeneration, Alzheimer Disease, and dementia: record linkage study of hospital admissions. JAMA Ophthalmol 2013; 132: 63-8.
60. Klein R, Knudtson MD, Klein BE. Statin use and the five-year incidence and progression of age-related macular degeneration. Am J Ophthalmol 2007; 144: 1-6.
61. van Leeuwen R, Klaver CC, Vingerling JR et al. Cholesterol and age-related macular degeneration: is there a link? Am J Ophthalmol 2004; 137: 750-2.
62. Kabasawa S, Mori K, Horie-Inoue K et al. Associations of cigarette smoking but not serum fatty acids with age-related macular degeneration in a Japanese population. Ophthalmology 2011; 118: 1082-8.
63. Klein R, Knudtson MD, Lee KE, Klein BE. Serum cystatin C level, kidney disease markers, and incidence of age-related macular degeneration: the Beaver Dam Eye study. Arch Ophthalmol 2009; 127: 193-9.
64. Liew G, Mitchell P, Wong TY, Iyengar SK, Wang JJ. CKD increases the risk of age-related macular degeneration. J Am Soc Nephrol 2008; 19: 806-11.
65. Weiner DE, Tighiouart H, Reynolds R, Seddon JM. Kidney function, albuminuria and age-related macular degeneration in NHANES III. Nephrol Dial Transplant 2011; 26: 3159-65.
66. Wong CW, Wong TY, Cheng CY, Sabanayagam C. Kidney and eye diseases: common risk factors, etiological mechanisms, and pathways. Kidney Int. 2013; doi: 10.1038/ki.2013.491. [Epub ahead of print].
67. Xing C, Sivakumaran TA, Wang JJ et al. Complement factor H polymorphisms, renal phenotypes and age-related macular degeneration: the Blue Mountains Eye study. Genes Immun 2008; 9: 231-9.
68. Hahn P, Acquah K, Cousins SW, Lee PP, Sloan FA. Ten-year incidence of age-related macular degeneration according to diabetic retinopathy classification among medicare beneficiaries. Retina 2013; 33: 911-9.
69. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL 3rd, Age-Related Eye Disease Study Research Group. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease study (AREDS) AREDS report no. 19. Ophthalmology 2005; 112: 533-9.
70. Seddon JM, Cote J, Davis N, Rosner B. Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol 2003; 121: 785-92.
71. Fraser-Bell S, Wu J, Klein R, Azen SP, Varma R. Smoking, alcohol intake, estrogen use, and age-related macular degeneration in Latinos: the Los Angeles Latino Eye study. Am J Ophthalmol 2006; 141: 79-87.
72. Bromfield S, Keenan J, Jolly P, McGwin G Jr. A suggested association between hypothyroidism and age-related macular degeneration. Curr Eye Res 2012; 37: 549-52.
73. Klein R, Klein BE, Myers CE. Risk assessment models for late age-related macular degeneration. Arch Ophthalmol 2011; 129: 1605-6.
74. Cugati S, Cumming RG, Smith W, Burlutsky G, Mitchell P, Wang JJ. Visual impairment, age-related macular degeneration, cataract, and long-term mortality: the Blue Mountains Eye study. Arch Ophthalmol 2007; 125: 917-24.
75. Clemons TE, Kurinij N, Sperduto RD, Group AR. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease study: AREDS report no. 13. Arch Ophthalmol 2004; 122: 716-26.
76. Wang JJ, Mitchell P, Simpson JM, Cumming RG, Smith W. Visual impairment, age-related cataract, and mortality. Arch Ophthalmol 2001; 119: 1186-90.
77. Borger PH, van Leeuwen R, Hulsman CAA et al. Is there a direct association between age-related eye diseases and mortality? Ophthalmology 2003; 110: 1292-6.
78. Ikram MK, Mitchell P, Klein R, Sharrett AR, Couper DJ, Wong TY. Age-related macular degeneration and long-term risk of stroke subtypes. Stroke 2012; 43: 1681-3.
79. Wong TY, Klein R, Sun C et al. Age-related macular degeneration and risk for stroke. Ann Intern Med 2006; 145: 98-106.
80. Hu CC, Ho JD, Lin HC. Neovascular age-related macular degeneration and the risk of stroke: a 5-year population-based follow-up study. Stroke 2010; 41: 613-7.
81. Liao D, Mo J, Duan Y et al. Is age-related macular degeneration associated with stroke among elderly americans? Open Ophthalmol J 2008; 2: 37-42.
82. Duan Y, Mo J, Klein R et al. Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans. Ophthalmology 2007; 114: 732-7.
83. Fernandez AB, Wong TY, Klein R et al. Age-related macular degeneration and incident cardiovascular disease: the Multi-Ethnic study of Atherosclerosis. Ophthalmology 2012; 119: 765-70.
84. Cong R, Zhou B, Sun Q, Gu H, Tang N, Wang B. Smoking and the risk of age-related macular degeneration: a meta-analysis. Ann Epidemiol 2008; 18: 647-56.
85. Cackett P, Wong TY, Aung T et al. Smoking, cardiovascular risk factors, and age-related macular degeneration in Asians: the Singapore Malay Eye study. Am J Ophthalmol 2008; 146: 960-7.e961.
86. Seddon JM, George S, Rosner B. Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: the US Twin Study of Age-Related Macular Degeneration. Arch Ophthalmol 2006; 124: 995-1001.
87. La Torre G, Pacella E, Saulle R et al. The synergistic effect of exposure to alcohol, tobacco smoke and other risk factors for age-related macular degeneration. Eur J Epidemiol 2013; 28: 445-6.
88. Wang JJ, Ross RJ, Tuo J et al. The LOC387715 polymorphism, inflammatory markers, smoking, and age-related macular degeneration. A population-based case-control study. Ophthalmology 2008; 115: 693-9.
89. Schmidt S, Hauser MA, Scott WK et al. Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. Am J Hum Genet 2006; 78: 852-64.
90. Sin HP, Liu DT, Lam DS. Lifestyle modification, nutritional and vitamins supplements for age-related macular degeneration. Acta Ophthalmol 2013; 91: 6-11.
91. Tan JS, Wang JJ, Flood V, Rochtchina E, Smith W, Mitchell P. Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye study. Ophthalmology 2008; 115: 334-41.
92. Chew EY, Clemons TE, Agron E et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology 2013; 120: 1604-11.
93. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease study 2 (AREDS2) randomized clinical trial. JAMA 2013; 309: 2005-15.
94. Group AR, Chew EY, Clemons T et al. The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology 2012; 119: 2282-9.
95. Musch DC. Evidence for including lutein and zeaxanthin in oral supplements for age-related macular degeneration. JAMA Ophthalmol 2014; 132: 139-41.
96. Souied EH, Delcourt C, Querques G et al. Oral docosahexaenoic acid in the prevention of exudative age-related macular degeneration: the Nutritional AMD Treatment 2 study. Ophthalmology 2013; 120: 1619-31.
97. Moriarty-Craige SE, Ha KN, Sternberg P Jr et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. Am J Ophthalmol 2007; 143: 206-11.
98. Christen WG, Glynn RJ, Sesso HD et al. Vitamins E and C and medical record-confirmed age-related macular degeneration in a randomized trial of male physicians. Ophthalmology 2012; 119: 1642-9.
99. de Jong PT, Chakravarthy U, Rahu M et al. Associations between aspirin use and aging macula disorder: the European Eye study. Ophthalmology 2012; 119: 112-8.
100. Klein BE, Howard KP, Gangnon RE, Dreyer JO, Lee KE, Klein R. Long-term use of aspirin and age-related macular degeneration. JAMA 2012; 308: 2469-78.
101. Liew G, Mitchell P, Wong TY, Rochtchina E, Wang JJ. The association of aspirin use with age-related macular degeneration. JAMA Intern Med 2013; 173: 258-64.
102. Cheung N, Tay WT, Cheung GC, Wang JJ, Mitchell P, Wong TY. Is aspirin intake associated with early age-related macular degeneration? The Singapore Indian Eye study. Br J Ophthalmol 2013; 97: 785-8.
103. Girgis RA, McKee HD. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol 2004; 138: 697; author reply 697-698.
104. Wilson HL, Schwartz DM, Bhatt HR, McCulloch CE, Duncan JL. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol 2004; 137: 615-24.
105. Wong TY, Rogers SL. Statins and age-related macular degeneration: time for a randomized controlled trial? Am J Ophthalmol 2007; 144: 117-9.
106. McGwin G Jr, Xie A, Owsley C. The use of cholesterol-lowering medications and age-related macular degeneration. Ophthalmology 2005; 112: 488-94.
107. Tan JS, Mitchell P, Rochtchina E, Wang JJ. Statins and the long-term risk of incident age-related macular degeneration: the Blue Mountains Eye study. Am J Ophthalmol 2007; 143: 685-7.
108. Gehlbach P, Li T, Hatef E. Statins for age-related macular degeneration. Cochrane Database Syst Rev 2012; 3: CD006927.
109. Wong TY. Age-related macular degeneration and cardiovascular disease in the era of anti-vascular endothelial growth factor therapies. Am J Ophthalmol 2009; 148: 327-9.
110. Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2009; 20: 158-65.
111. Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age-related macular degeneration. Lancet 2007; 370: 204-6.
112. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300: 2277-85.
113. Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 2010; 94: 1215-8.
114. Lim LS, Cheung CM, Mitchell P, Wong TY. Emerging evidence concerning systemic safety of anti-VEGF agents-should ophthalmologists be concerned? Am J Ophthalmol 2011; 152: 329-31.
115. Schmucker C, Ehlken C, Agostini HT et al. A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS ONE 2012; 7: e42701.
116. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011; 56: 95-113.
117. Campbell RJ, Bell CM, Paterson JM et al. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis. Ophthalmology 2012; 119: 1604-8.
118. Bressler NM, Boyer DS, Williams DF et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina 2012; 32: 1821-8.
119. Kemp A, Preen DB, Morlet N et al. Myocardial infarction after intravitreal vascular endothelial growth factor inhibitors: a whole population study. Retina 2013; 33: 920-7.
120. Gillies MC, Wong TY. Ranibizumab for neovascular age-related macular degeneration. New Engl J Med 2007;356: 748-9; author reply 749-750.
121. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114: 855-9.
122. Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010; 128: 1273-9.
123. Fritsche LG, Chen W, Schu M et al. Seven new loci associated with age-related macular degeneration. Nat Genet 2013; 45: 433-9, 439e1-2.
124. Ratnapriya R, Chew EY. Age-related macular degeneration-clinical review and genetics update. Clin Genet 2013; 84: 160-6.
125. Hageman GS, Anderson DH, Johnson LV et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005; 102: 7227-32.
126. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308: 421-4.
127. Klein RJ, Zeiss C, Chew EY et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308: 385-9.
128. Rivera A, Fisher SA, Fritsche LG et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet 2005; 14: 3227-36.
129. Yang Z, Camp NJ, Sun H et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 2006; 314: 992-3.
130. Klein R, Knudtson MD, Klein BE et al. Inflammation, complement factor h, and age-related macular degeneration: the Multi-ethnic Study of Atherosclerosis. Ophthalmology 2008; 115: 1742-9.
131. de Cordoba SR, Tortajada A, Harris CL, Morgan BP. Complement dysregulation and disease: from genes and proteins to diagnostics and drugs. Immunobiology 2012; 217: 1034-46.
132. Parmeggiani F, Romano MR, Costagliola C et al. Mechanism of inflammation in age-related macular degeneration. Mediators Inflamm 2013; 2013: 435607.
133. Vine AK, Stader J, Branham K, Musch DC, Swaroop A. Biomarkers of cardiovascular disease as risk factors for age-related macular degeneration. Ophthalmology 2005; 112: 2076-80.
134. Robman L, Baird PN, Dimitrov PN, Richardson AJ, Guymer RH. C-reactive protein levels and complement factor H polymorphism interaction in age-related macular degeneration and its progression. Ophthalmology 2010; 117: 1982-8.
135. Rochtchina E, Wang JJ, Flood VM, Mitchell P. Elevated serum homocysteine, low serum vitamin B12, folate, and age-related macular degeneration: the Blue Mountains Eye study. Am J Ophthalmol 2007; 143: 344-6.
136. Seddon JM, George S, Rosner B, Rifai N. Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch Ophthalmol 2005; 123: 774-82.
137. Shankar A, Mitchell P, Rochtchina E, Tan J, Wang JJ. Association between circulating white blood cell count and long-term incidence of age-related macular degeneration: the Blue Mountains Eye study. Am J Epidemiol 2007; 165: 375-82.
138. Seddon JM, Gensler G, Rosner B. C-reactive protein and CFH, ARMS2/HTRA1 gene variants are independently associated with risk of macular degeneration. Ophthalmology 2010; 117: 1560-6.
139. Mitta VP, Christen WG, Glynn RJ et al. C-reactive protein and the incidence of macular degeneration: pooled analysis of 5 cohorts. JAMA Ophthalmol 2013; 131: 507-13.
140. Seddon JM, Reynolds R, Yu Y, Rosner B. Validation of a prediction algorithm for progression to advanced macular degeneration subtypes. JAMA Ophthalmol 2013; 131: 448-55.
141. Buitendijk GH, Rochtchina E, Myers C et al. Prediction of age-related macular degeneration in the general population: the Three Continent AMD Consortium. Ophthalmology 2013; 120: 2644-55.
142. Keilhauer CN, Fritsche LG, Guthoff R, Haubitz I, Weber BH. Age-related macular degeneration and coronary heart disease: evaluation of genetic and environmental associations. Eur J Med Genet 2013; 56: 72-9.
143. Conley YP, Jakobsdottir J, Mah T et al. CFH, ELOVL4, PLEKHA1 and LOC387715 genes and susceptibility to age-related maculopathy: AREDS and CHS cohorts and meta-analyses. Hum Mol Genet 2006; 15: 3206-18.
144. Neale BM, Fagerness J, Reynolds R et al. Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC). Proc Natl Acad Sci USA 2010; 107: 7395-400.
145. Merle BM, Maubaret C, Korobelnik JF et al. Association of HDL-related loci with age-related macular degeneration and plasma lutein and zeaxanthin: the Alienor study. PLoS ONE 2013; 8: e79848.
146. Reynolds R, Rosner B, Seddon JM. Serum lipid biomarkers and hepatic lipase gene associations with age-related macular degeneration. Ophthalmology 2010; 117: 1989-95.
147. Khandhadia S, Foster S, Cree A et al. Chlamydia infection status, genotype, and age-related macular degeneration. Mol Vis 2012; 18: 29-37.
148. Robman L, Mahdi OS, Wang JJ et al. Exposure to Chlamydia pneumoniae infection and age-related macular degeneration: the Blue Mountains Eye study. Invest Ophthalmol Vis Sci 2007; 48: 4007-11.
149. Rennie CA, Stinge A, King EA, Sothirachagan S, Osmond C, Lotery AJ. Can genetic risk information for age-related macular degeneration influence motivation to stop smoking? A pilot study Eye 2012; 26: 109-18.
150. Wang JJ, Rochtchina E, Smith W et al. Combined effects of complement factor H genotypes, fish consumption, and inflammatory markers on long-term risk for age-related macular degeneration in a cohort. Am J Epidemiol 2009; 169: 633-41.
151. Priya RR, Chew EY, Swaroop A. Genetic studies of age-related macular degeneration: lessons, challenges, and opportunities for disease management. Ophthalmology 2012; 119: 2526-36.
152. Stone EM, Aldave AJ, Drack AV et al. Recommendations for genetic testing of inherited eye diseases: report of the American Academy of Ophthalmology task force on genetic testing. Ophthalmology 2012; 119: 2408-10.
153. Kikuchi M, Nakamura M, Ishikawa K et al. Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration. Ophthalmology 2007; 114: 1722-7.
154. Cackett P, Yeo I, Cheung CM et al. Relationship of smoking and cardiovascular risk factors with polypoidal choroidal vasculopathy and age-related macular degeneration in Chinese persons. Ophthalmology 2011; 118: 846-52.
155. Ueta T, Obata R, Inoue Y et al. Background comparison of typical age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 2009; 116: 2400-6.
156. Zhang X, Li M, Wen F et al. Different impact of high-density lipoprotein-related genetic variants on polypoidal choroidal vasculopathy and neovascular age-related macular degeneration in a Chinese Han population. Exp Eye Res 2013; 108: 16-22.
157. Sakurada Y, Yoneyama S, Imasawa M, Iijima H. Systemic risk factors associated with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration. Retina 2013; 33: 841-5.
158. Cheung CM, Wong TY. Treatment of age-related macular degeneration. Lancet 2013; 382: 1230-2.
159. Cheung CM, Bhargava M, Laude A et al. Asian age-related macular degeneration phenotyping study: rationale, design and protocol of a prospective cohort study. Clin Experiment Ophthalmol 2012; 40: 727-35.
160. Reynolds R, Rosner B, Seddon JM. Dietary omega-3 fatty acids, other fat intake, genetic susceptibility, and progression to incident geographic atrophy. Ophthalmology 2013; 120: 1020-8.